In this episode, we review the ISAR-REACT 5 trial and hear Dr. Steve Dunn’s thoughts about how this trial fits into P2Y12 management in patients with acute coronary syndromes.
Episode: 0:00-0:40: Intro 0:41-1:23: Introduction of Dr. Steve Dunn 1:24-3:42: ISAR-REACT 5 Overview 3:43-6:28: Steve’s Overall Thoughts 6:29-7:59: Context of ISAR-REACT 5 8:00-9:34: Study Funding 9:35-11:25: Study Discontinuation Rate 11:26-12:50: Secondary Safety Outcomes 12:51-15:51: Final Thoughts 15:52-16:50: Closing/Podcast Recording Location Discussion
ISAR-REACT 5: Schüpke S, Neumann F, Menichelli M, et al. Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. N Engl J Med 2019;381:1524-1534.
TRITON-TIMI: Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med 2009;357:2001-2015.
PLATO: Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med 2009;361:1045-1057.
PRAGUE-18: Motovska Z, Hlinomaz O, Miklik R, et al. Prasugrel Versus Ticagrelor in Patients With Acute Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention: Multicenter Randomized PRAGUE-18 Study. Circulation 2016;134(21):1603-1612.
TRILOGY-ACS: Roe MT, Armstrong PW, Fox KA, et al. Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization. N Engl J Med 2012;367:1297-1309.
ACCOAST: Montalescot G, Bolognese L, Dudek D, et al. Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes. N Engl J Med 2013;369:999-1010.
REACT(5)ion from Steve Dunn: Feeling conflicted about which P2Y12 inhibitor to use since ISAR-REACT 5 was released? Listen to Steve’s REACT(5)ion here first!
How sweet it is to be an SGLT2 Inhibitor: Listen to Dr. Ted Berei’s thoughts about dapagliflozin use in patients with heart failure and reduced ejection fraction.
Entering the TWILIGHT Zone: In this episode, we’ll talk to Dr. Craig Beavers about his thoughts on the TWILIGHT trial and discuss his aspiring future podcast combining cardiology with pop culture! Anticipated release of 2024…
In Zac Noel we ENTRUST: Double or Nothing?: A few recent trials have evaluated triple antithrombotic therapy vs. dual antithrombotic therapy in patients with ACS/PCI and AF. In this episode, we put our full (en)TRUST in Dr. Zac Noel as he helps us navigate this complex clinical conundrum.
“Been There, Done That”- Expert Advice From Parting RPDs: In this special two-part episode former Cardiology Residency Program Director Tracy Macaulay, interviews Dr. Kerry Pickworth and Dr. Robert Didomenico, former RPDs at Ohio State and University of Illinois at Chicago, respectively. Words of wisdom are pulled from a recently published opinion paper on recommendations for training cardiovascular pharmacy specialists and tricks on finding the right match this recruitment season.
In this episode, we interview Dr. Tracy Macaulay about the AFIRE trial and hear her thoughts on the role of aspirin in patients with atrial fibrillation and stable coronary disease.
Episode: 0:00-1:38: Intro 1:39-2:35: Introduction of Dr. Tracy Macaulay 2:36-5:19: AFIRE Trial Overview 5:20-7:14: Initial Thoughts 7:15-10:07: AFIRE Population and Rivaroxaban Dosing 10:08-11:06: Dropping Aspirin 11:07-12:11: What about other anticoagulants? 12:12-13:38: Final Thoughts 13:39-14:50: Closing/Discussion of Funding
AFIRE Trial: Yasuda S, Kaikita K, Akao M, et al. Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med 2019;381:1103-1113.
OAC-ALONE Trial: Matsumura-Nakano Y, Shizuta S, Komasa A, et al. Open-label randomized trial comparing oral anticoagulation with and without single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond 1 year after coronary stent implantation: OAC-ALONE Study. Circulation 2019; 139:604–616.
WARIS-II Trial: Hurlen M, Abdelnoor M, Smith P, et al. Warfarin, Aspirin, or Both after Myocardial Infarction. N Engl J Med 2002;347:969-974.
J-ROCKET AF Study: Hori M, Matsumoto M, Tanahashi N, et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation — the J-ROCKET AF Study. Circ J 2012;76:2104-11.
Other: Tanigawa T, Kaneko M, Hashizume K, et al. Model-based dose selection for phase III rivaroxaban study in Japanese patients with non-valvular atrial fibrillation. Drug Metab Pharmacokinet 2013;28:59-70.
Feel like something’s missing? Looking for a way to keep up-to-date with cardiology literature? Then you are listening to the right podcast! CardioScripts is a cardiology pharmacy podcast intended to help keep you up-to-date in a fun, engaging, and efficient manner. Join hosts Tracy Macaulay and Liz Sulaica as they interview cardiology pharmacy experts across the country!